No matches

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United Arab EmiratesChange country/region

Pulmonology

Marc Miravitlles

MD, FERS

Senior Researcher and Consultant Pneumology Department Vall d’Hebron University Hospital/Vall d’Hebron Research Institute

Biography

Marc Miravitlles, MD, FERS, is a senior researcher and a consultant in the Pneumology Department at the Vall d’Hebron University Hospital and the Vall d’Hebron Research Institute in Barcelona, Spain. He has served as chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and guidelines director of the ERS. He has also acted as a consultant for the development of international guidelines of chronic obstructive pulmonary disease (COPD), including the American Thoracic Society (ATS)/ERS guidelines on exacerbations of COPD and the ERS statement on the management of respiratory disease in alpha-1 antitrypsin deficiency. He is currently a consultant to the Spanish Ministry of Health for the development of the National Strategy Against COPD and the vice president of the ERS (2024-2025). In addition, he has served as the coordinator of the Spanish National Guidelines for COPD since 2011. Dr Miravitlles is the author or coauthor of more than 650 peer-reviewed publications in the fields of COPD and alpha-1 antitrypsin deficiency.